Table 3.

Effect of clinical variables on SC CT-P13 treatment persistence at latest follow-up.

Variable	Regression co-efficient	95% CI	p-value
UC vs CD	2.068	0.441, 9.696	0.357
Clinically active disease	1.277	0.224, 7.296	0.783
Perianal disease	4.001	0.723, 22.145	0.112
CRP >5 mg/L	0.649	0.072, 5.861	0.700
Dosing regimen [weekly/EOW]	0.625	0.072, 5.411	0.669
Concomitant immunomodulators	0.661	0.183, 2.383	0.527
Antibodies to infliximab	2.102	0.196, 22.523	0.539

SC, subcutaneous; UC, ulcerative colitis; CD, Crohn’s disease; EOW, every other week; CI, confidence interval; CRP, C-reactive protein.